Functional Neurological Disorders in Patients Admitted in Stroke Units (NEUROFON)
Functional Neurological Disorders in Patients Admitted in Stroke Units: Clinical Profile et and 6 Months Follow-up
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Sarah BENISTY
- Phone Number: 01 48 03 67 14
- Email: sbenisty@for.paris
Study Contact Backup
- Name: Amelie Yavchitz, PhD
- Phone Number: 01 48 03 64 54
- Email: ayavchitz@for.paris
Study Locations
-
-
Paris
-
Paris, Paris, France, 75019
- Hopital Fondation Adolphe de Rothschild
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age over 18 years old
- Patients admitted in stroke unit for a neurological deficit, without evidence of neurovascular or othe neurological disease.
- NIHSS ≥ 1 at time of admission
- Informed and consent patient to study
- Health insured
Exclusion Criteria:
- Patient receiving legal protection
- Pregnant or breastfeeding woman
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Patients
|
description of the cognitive and behavioral profile of stroke mimics patients, without evidence of neurological disease.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Patient characteristics
Time Frame: 3 months
|
Cognitive/behavioural characteristics of patients assessed for stroke using the National Institute of Health Stroke Score ranging from 0 to 42 (0: no stroke; 1-4: minor stroke; 5-15: moderate stroke; moderate to severe stroke; 21-42: severe stroke)
|
3 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
symptoms of patients
Time Frame: 3 and 6 months
|
Description of symptoms at 3 and 6 months after transition in stroke unit
|
3 and 6 months
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- SBY_2020_1
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.